In Currax's new campaign for weight loss med Contrave, the focus is on emotional eating — reaching for cookies for comfort, for instance.

August 31, 2022 02:40 PM EDTUpdated 07:05 PM

Marketing

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Beth Snyder Bulik

Senior Editor

Obesity is in the spotlight thanks to a raft of new and pending therapies in the pipeline. However, Currax Pharmaceuticals’ Contrave, the old guard of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Cur­rax dou­bles down on ‘pi­o­neer’ weight-loss med Con­trave in new­ly en­er­gized obe­si­ty drug mar­ket

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings